Chris Z Wei, Mark W Youngblood, Jheremy S Reyes, Maciej S Lesniak, Pouya Jamshidi, David R Raleigh, Amy B Heimberger, Stephen T Magill, Constantinos G Hadjipanayis
{"title":"Rethinking Meningioma Biology: Integrating Molecular and Microenvironmental Insights for Mechanism-Guided Therapy.","authors":"Chris Z Wei, Mark W Youngblood, Jheremy S Reyes, Maciej S Lesniak, Pouya Jamshidi, David R Raleigh, Amy B Heimberger, Stephen T Magill, Constantinos G Hadjipanayis","doi":"10.1146/annurev-med-061826-092908","DOIUrl":"https://doi.org/10.1146/annurev-med-061826-092908","url":null,"abstract":"<p><p>Meningiomas are the most common primary intracranial tumors, accounting for 42.6% of all central nervous system tumors. Although many meningiomas are indolent, clinical behavior is highly heterogeneous, with recurrence occurring in a minority of low-risk tumors but in more than half of clinically high-risk cases despite standard therapy. During the past decade, significant advancements in molecular profiling have provided insights into meningioma biology and have begun to influence clinical practice. Genomic sequencing, DNA methylation profiling, and gene expression analyses have revealed distinct molecular subgroups with prognostic and therapeutic implications. These advancements, coupled with a growing understanding of the meningioma immune microenvironment, have expanded therapeutic possibilities beyond traditional surgery and radiation approaches. Here, we review how molecular profiling is refining patient stratification and treatment selection, examine the evidence supporting various therapeutic approaches, and explore ongoing clinical trials. Finally, we highlight the critical challenges in advancing personalized medicine for meningioma patients. This comprehensive review provides an integrated overview of current diagnostic and treatment paradigms while offering perspectives on future directions in meningioma therapy.</p>","PeriodicalId":8056,"journal":{"name":"Annual review of medicine","volume":" ","pages":""},"PeriodicalIF":18.8,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Navneet Sohi, Rishi B Gupta, Suhani K Arora, Harpreet S Bajaj
{"title":"Rapidly Evolving Insulin Landscape: Ultrashort Acting and Ultralong Acting.","authors":"Navneet Sohi, Rishi B Gupta, Suhani K Arora, Harpreet S Bajaj","doi":"10.1146/annurev-med-042425-010403","DOIUrl":"https://doi.org/10.1146/annurev-med-042425-010403","url":null,"abstract":"<p><p>Since the discovery of insulin in 1921, there has been remarkable evolution in insulin treatment for diabetes, with modern insulin analogues utilizing highly engineered recombinant technology. The purpose of this review is to focus on two revolutionary developments in contemporary insulin therapy: once-weekly ultralong-acting basal insulins and ultrashort-acting bolus insulins. Insulin icodec and insulin efsitora alfa represent a unique shift in basal insulin delivery, offering the convenience of once-weekly administration, flat pharmacokinetic profiles, and glycemic efficacy and safety comparable to those of daily basal analogues while reducing injection burden and improving patient satisfaction. With regard to bolus therapy, faster-acting aspart and ultrarapid lispro achieve accelerated absorption through novel excipient engineering, enabling more flexible mealtime dosing and improved postprandial glucose control compared to their traditional counterparts. Looking ahead, there are promising innovations on the horizon, including glucose-responsive insulins, artificial intelligence-driven automated insulin delivery, and the continued pursuit of oral insulin. Together, these advances represent an accelerating trajectory toward more physiological, convenient, and, most importantly, safe insulin therapy.</p>","PeriodicalId":8056,"journal":{"name":"Annual review of medicine","volume":" ","pages":""},"PeriodicalIF":18.8,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Use of Biologics and Immune Checkpoint Inhibitors During Pregnancy in Patients with Systemic Autoimmune Diseases and Cancer.","authors":"Brooke S Mills, Bonnie L Bermas","doi":"10.1146/annurev-med-042425-044110","DOIUrl":"https://doi.org/10.1146/annurev-med-042425-044110","url":null,"abstract":"<p><p>Biologics and immune checkpoint inhibitors have transformed the treatment of autoimmune conditions and cancers. However, safety data regarding use during pregnancy are limited. Clinicians are left to weigh the potential benefits of treatment with frequently unknown risks to the pregnant patient and developing fetus. These therapies do not cross the placenta during the first trimester; thus, they are unlikely to cause teratogenicity. Use later in pregnancy has the potential to immunosuppress the neonate, which could lead to infection and inadequate vaccine response. These large molecules are minimally transferred into breastmilk and are mostly compatible with nursing.</p>","PeriodicalId":8056,"journal":{"name":"Annual review of medicine","volume":" ","pages":""},"PeriodicalIF":18.8,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149357070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Conservative Management of Kidney Failure.","authors":"Jordana Yahr, Jane O Schell, Samantha L Gelfand","doi":"10.1146/annurev-med-042425-022821","DOIUrl":"https://doi.org/10.1146/annurev-med-042425-022821","url":null,"abstract":"<p><p>The default therapy for end-stage kidney disease is often dialysis, but for those with advanced age and multimorbidity, it may not provide significant benefit to longevity or quality of life. Conservative management (CM) is a holistic care pathway for those whose care preferences do not align with dialysis. CM aims to optimize quality of life over the disease course as patient priorities evolve and their disease progresses. Components of CM include customized chronic kidney disease care, symptom management, and navigation of transitions of care, including end-of-life care. Nephrology clinicians are the central providers of CM and ideally collaborate with a multidisciplinary team to provide medical, psychosocial, and spiritual care.</p>","PeriodicalId":8056,"journal":{"name":"Annual review of medicine","volume":" ","pages":""},"PeriodicalIF":18.8,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149284698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"T Cell Receptor-Engineered T Cell Therapy in Solid Tumors: Where We Stand and What's to Come.","authors":"Candela Ferriol-Martínez, Sandra P D'Angelo","doi":"10.1146/annurev-med-042425-051841","DOIUrl":"https://doi.org/10.1146/annurev-med-042425-051841","url":null,"abstract":"<p><p>T cell receptor-engineered T (TCR-T) cell therapy has emerged as a promising adoptive cellular therapy for solid tumors by enabling recognition of intracellular antigens presented via human leukocyte antigen (HLA) molecules. Unlike chimeric antigen receptor T cell therapy, TCR-T cell therapy targets a broader antigen repertoire, including cancer-testis antigens, neoantigens, and viral antigens. Recent clinical advances, highlighted by the approval of afamitresgene autoleucel in synovial sarcoma, demonstrate meaningful antitumor activity. However, several limitations remain, including HLA restriction, antigen heterogeneity, toxicity related to on-target/off-tumor effects, and mechanisms of resistance such as antigen loss and T cell exhaustion. Advances in antigen selection, gene editing, and synthetic biology are improving both safety and efficacy. Combination strategies and next-generation engineered constructs are expected to overcome current barriers. This review summarizes the biological rationale, clinical evidence, safety considerations, and resistance mechanisms of TCR-T cell therapy in solid tumors and discusses future directions to optimize their therapeutic potential.</p>","PeriodicalId":8056,"journal":{"name":"Annual review of medicine","volume":" ","pages":""},"PeriodicalIF":18.8,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149242656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
James D R Hartley, Anika Singanayagam, Daniel H Goldhill
{"title":"The Risk of an H5N1 Influenza Pandemic.","authors":"James D R Hartley, Anika Singanayagam, Daniel H Goldhill","doi":"10.1146/annurev-med-042525-092552","DOIUrl":"https://doi.org/10.1146/annurev-med-042525-092552","url":null,"abstract":"<p><p>The last 110 years have seen four influenza A pandemics, where viruses have emerged from mammals or birds with the ability to transmit and cause disease in human populations. Since 2021, a high-pathogenicity strain of avian influenza, H5N1, has caused a panzootic (pandemic of animals), with global spread in wild birds, resulting in frequent spillovers into farmed poultry and into mammals, including mammal species not previously known to be affected by influenza A. This has created increased opportunity for reassortment, mutation, human infection, and potential adaptation to transmit. The risk to humans and the impact are difficult to quantify but of mounting concern to public health bodies. Here, we examine the risk of an H5N1 pandemic emerging and spreading in humans and the potential impact of an H5N1 pandemic.</p>","PeriodicalId":8056,"journal":{"name":"Annual review of medicine","volume":" ","pages":""},"PeriodicalIF":18.8,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Treatment of Tricuspid Valve Disease.","authors":"Elina Pliakos, Suzanne J Baron","doi":"10.1146/annurev-med-042525-084459","DOIUrl":"https://doi.org/10.1146/annurev-med-042525-084459","url":null,"abstract":"<p><p>In the landscape of valvular heart disease, the tricuspid valve has traditionally been dubbed the forgotten valve. However, over the last several years, studies have demonstrated that tricuspid valve disease is increasing in prevalence due to a growing aging population, and tricuspid regurgitation, in particular, is associated with increased mortality and morbidity. Traditional surgical tricuspid valve replacement or repair is often an undesirable option for patients with severe tricuspid regurgitation due to the high rates of concurrent comorbidities seen in this patient population; accordingly, treatment has traditionally been largely confined to symptom management with medical therapy. More recently, however, the field has experienced a major paradigm shift toward transcatheter interventions. Pivotal trials evaluating transcatheter edge-to-edge repair and transcatheter tricuspid valve replacement have shown that these therapies safely achieve robust tricuspid regurgitation reduction, reduce heart failure hospitalization, and significantly improve patient-reported quality of life in the short term. These technologies have been key in providing treatment options for a large, previously underserved patient population, but further research is needed to establish the durability of these devices and to evaluate the cost-effectiveness of these interventions within a value-based healthcare framework.</p>","PeriodicalId":8056,"journal":{"name":"Annual review of medicine","volume":" ","pages":""},"PeriodicalIF":18.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149103191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Melanie A Babinski, Ruth J F Loos, Sonja I Berndt, Joel N Hirschhorn
{"title":"Genetics of Obesity: Discovery, Biology, Prediction, and Therapeutic Implications.","authors":"Melanie A Babinski, Ruth J F Loos, Sonja I Berndt, Joel N Hirschhorn","doi":"10.1146/annurev-med-060123-120428","DOIUrl":"https://doi.org/10.1146/annurev-med-060123-120428","url":null,"abstract":"<p><p>With the rise in its prevalence, obesity has become a public health threat worldwide. Understanding the genetic and biological origins of obesity is critical for discovering and implementing better prevention and treatment strategies to combat its dominance and impact on disease risk. This review summarizes current knowledge about the genetic architecture of obesity, including the contribution of rare and common variants to monogenic and polygenic forms of obesity. It discusses the biological underpinnings of discovered genetic loci and how these mechanistic insights may suggest new potential therapeutic drug targets. Lastly, it explores how these genetic discoveries may aid in the prediction of future obesity, particularly in children and young adults, and lead to more effective prevention strategies for obesity and related diseases, including cardiovascular disease, type 2 diabetes, and cancer.</p>","PeriodicalId":8056,"journal":{"name":"Annual review of medicine","volume":" ","pages":""},"PeriodicalIF":18.8,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149103128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Artificial Intelligence and Radiomics in the Diagnosis and Management of Cancer.","authors":"Lucas Patel, Albert Song, Albert Hsiao","doi":"10.1146/annurev-med-042325-094452","DOIUrl":"10.1146/annurev-med-042325-094452","url":null,"abstract":"<p><p>Imaging is increasingly essential for the diagnosis, prognostication, and management of cancer patients. It is a field in rapid evolution and has the potential to provide noninvasive characterization of malignancy, which remains an important Holy Grail of medicine. Radiomics, which involves the high-throughput assessment of imaging features, aims to transform images into structured phenotypic data. By correlating imaging-derived data with clinical and molecular information, radiomics offers the potential to relate tumor biology to imaging phenotype to improve patient prognostication and management. This review surveys the principles and applications of classical and deep learning-based radiomic approaches in oncology, and it highlights key challenges in robustness and reproducibility that must be addressed to realize the potential of radiomics in clinical practice.</p>","PeriodicalId":8056,"journal":{"name":"Annual review of medicine","volume":" ","pages":""},"PeriodicalIF":18.8,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13761957/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149001166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Genomic Screening for Infants and Reproductive Adults.","authors":"Stephen F Kingsmore, Martin Delatycki","doi":"10.1146/annurev-med-042425-014721","DOIUrl":"https://doi.org/10.1146/annurev-med-042425-014721","url":null,"abstract":"<p><p>Recent progress in genomic sequencing, bioinformatics, cloud computation, and artificial intelligence is advancing a more mature understanding of the architecture of childhood genetic diseases. This knowledge and these technologies are enabling expanded genomic screening of infant and reproductive adult populations. With many new disease-modifying and curative therapies in development and approval processes, there exists unparalleled opportunity to identify, treat, and decrease the population burden of genetic disease and transform medical genetics. Broad implementation of genomic population screening, however, requires investments for overcoming remaining evidence gaps and operational challenges, and for delivery in a sustainable manner that is acceptable to parents, prospective parents, and physicians.</p>","PeriodicalId":8056,"journal":{"name":"Annual review of medicine","volume":" ","pages":""},"PeriodicalIF":18.8,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148987786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}